治疗药物监测
抗生素
生物传感器
注意事项
血液取样
药品
加药
纳米技术
检测点注意事项
材料科学
生物医学工程
药理学
医学
微生物学
内科学
生物
免疫学
病理
作者
H. Ceren Ates,Hasti Mohsenin,Christin Wenzel,Regina Glatz,Hanna J. Wagner,Richard C. Bruch,Nico Höfflin,Sashko Spassov,Lea Streicher,Sara Lozano‐Zahonero,Bernd Flamm,Rainer Trittler,Martin Hug,Maja Köhn,Julius Schmidt,Stefan Schumann,G. Urban,Wilfried Weber,Can Dincer
标识
DOI:10.1002/adma.202104555
摘要
Personalized antibiotherapy ensures that the antibiotic concentration remains in the optimal therapeutic window to maximize efficacy, minimize side effects, and avoid the emergence of drug resistance due to insufficient dosing. However, such individualized schemes need frequent sampling to tailor the blood antibiotic concentrations. To optimally integrate therapeutic drug monitoring (TDM) into the clinical workflow, antibiotic levels can either be measured in blood using point-of-care testing (POCT), or can rely on noninvasive sampling. Here, a versatile biosensor with an antibody-free assay for on-site TDM is presented. The platform is evaluated with an animal study, where antibiotic concentrations are quantified in different matrices including whole blood, plasma, urine, saliva, and exhaled breath condensate (EBC). The clearance and the temporal evaluation of antibiotic levels in EBC and plasma are demonstrated. Influence of matrix effects on measured drug concentrations is determined by comparing the plasma levels with those in noninvasive samples. The system's potential for blood-based POCT is further illustrated by tracking ß-lactam concentrations in untreated blood samples. Finally, multiplexing capabilities are explored successfully for multianalyte/sample analysis. By enabling a rapid, low-cost, sample-independent, and multiplexed on-site TDM, this system can shift the paradigm of "one-size-fits-all" strategy.
科研通智能强力驱动
Strongly Powered by AbleSci AI